The pleiotropic actions of rosuvastatin confer renal benefits in the diabetic Apo-E knockout mouse

American Journal of Physiology - Renal Physiology

Volumn 299, Issue 3, 2010, Pages

  Giunti, Sara ^a   Calkin, Anna C ^a   Forbes, Josephine M ^a   Allen, Terri J ^a,b   Thomas, Merlin C ^a,b   Cooper, Mark E ^a   Jandeleit Dahm, Karin A ^a,b  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

Angiotensin type 1 receptor antagonist; Experimental diabetes; Kidney disease; Statin

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; APOLIPOPROTEIN E; BENZIMIDAZOLE DERIVATIVE; CANDESARTAN; FLUOROBENZENE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PYRIMIDINE DERIVATIVE; ROSUVASTATIN; STREPTOZOCIN; SULFONAMIDE; TETRAZOLE DERIVATIVE;

ANIMAL; BLOOD PRESSURE; COMPARATIVE STUDY; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; DISEASE MODEL; DRUG COMBINATION; DRUG EFFECTS; GENETICS; KIDNEY; KNOCKOUT MOUSE; LIPID METABOLISM; MALE; METABOLISM; MOUSE; OXIDATIVE STRESS; PATHOLOGY;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; APOLIPOPROTEINS E; BENZIMIDAZOLES; BLOOD PRESSURE; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; FLUOROBENZENES; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KIDNEY; LIPID METABOLISM; MALE; MICE; MICE, KNOCKOUT; OXIDATIVE STRESS; PYRIMIDINES; STREPTOZOCIN; SULFONAMIDES; TETRAZOLES;

EID: 77956493744     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00127.2010     Document Type: Article

References (25)

1. Calkin AC, Giunti S, Jandeleit-Dahm KA, Allen TJ, Cooper ME, Thomas MC. PPAR-alpha and -gamma agonists attenuate diabetic kidney disease in the apolipoprotein E knockout mouse. Nephrol Dial Transplant 21: 2399-2405, 2006. (Pubitemid 44644510)
2. Casey RG, Joyce M, Roche-Nagle G, Chen G, Bouchier-Hayes D. Pravastatin modulates early diabetic nephropathy in an experimental model of diabetic renal disease. J Surg Res 123: 176-181, 2005.
3. Cooper ME. The role of the renin-angiotensin-aldosterone system in diabetes and its vascular complications. Am J Hypertens 17:16S-20S, 2004.
4. Douglas K, O'Malley PG, Jackson JL. Meta-analysis: the effect of statins on albuminuria. Ann Intern Med 145: 117-124, 2006.
5. Fried LF. Effects of HMG-CoA reductase inhibitors (statins) on progression of kidney disease. Kidney Int 74: 571-576, 2008.
6. Fujii M, Inoguchi T, Maeda Y, Sasaki S, Sawada F, Saito R, Kobayashi K, Sumimoto H, Takayanagi R. Pitavastatin ameliorates albuminuria and renal mesangial expansion by downregulating NOX4 in db/db mice. Kidney Int 72: 473-480, 2007.
7. Gorin Y, Block K, Hernandez J, Bhandari B, Wagner B, Barnes JL, Abboud HE. Nox4 NAD(P)H oxidase mediates hypertrophy and fibronectin expression in the diabetic kidney. J Biol Chem 280: 39616-39626, 2005.
8. Haslinger-Löffler B. Multiple effects of HMG-CoA reductase inhibitors (statins) besides their lipid-lowering function. Kidney Int 74: 553-555, 2008.
9. Inman SR, Stowe NT, Cressman MD, Brouhard BH, Nally JV Jr, Satoh S, Satodate R, Vidt DG. Lovastatin preserves renal function in experimental diabetes. Am J Med Sci 317: 215-221, 1999. (Pubitemid 30349695)
10. Kolavennu V, Zeng L, Peng H, Wang Y, Danesh FR. Targeting of RhoA/ROCK signaling ameliorates progression of diabetic nephropathy independent of glucose control. Diabetes 57: 714-723, 2008.
11. Lassila M, Seah KK, Allen TJ, Thallas V, Thomas MC, Candido R, Burns WC, Forbes JM, Calkin AC, Cooper ME, Jandeleit-Dahm KA. Accelerated nephropathy in diabetic apolipoprotein E-knockout mouse: role of advanced glycation end products. J Am Soc Nephrol 15: 2125-2138, 2004.
12. Nakamura T, Ushiyama C, Hirokawa K, Osada S, Shimada N, Koide H. Effect of cerivastatin on urinary albumin excretion and plasma endothelin- 1 concentrations in type 2 diabetes patients with microalbuminuria and dyslipidemia. Am J Nephrol 21: 449-454, 2001. (Pubitemid 34088200)
13. Ota T, Takamura T, Ando H, Nohara E, Yamashita H, Kobayashi K. Preventive effect of cerivastatin on diabetic nephropathy through suppression of glomerular macrophage recruitment in a rat model. Diabetologia 46: 843-851, 2003.
14. Qin J, Zhang Z, Liu J, Sun L, Hu L, Cooper ME, Cao Z. Effects of the combination of an angiotensin II antagonist with an HMG-CoA reductase inhibitor in experimental diabetes. Kidney Int 64: 565-571, 2003.
15. Rosario RF, Prabhakar S. Lipids and diabetic nephropathy. Curr Diab Rep 6: 455-462, 2006.
16. Sidaway JE, Davidson RG, McTaggart F, Orton TC, Scott RC, Smith GJ, Brunskill NJ. Inhibitors of 3-hydroxy-3-methylglutaryl-CoA reductase reduce receptor-mediated endocytosis in Opossum kidney cells. J Am Soc Nephrology 15: 2258-2265, 2004. (Pubitemid 39159326)
17. Sourris KC, Forbes JM. Interactions between advanced glycation endproducts (AGE) and their receptors in the development and progression of diabetic nephropathy - are these receptors valid therapeutic targets. Curr Drug Targets 10: 42-50, 2009.
18. Tan AL, Forbes JM, Cooper ME. AGE, RAGE, and ROS in diabetic nephropathy. Semin Nephrol 27: 130-143, 2007.
19. Thomas MC, Rosengård-Bärlund M, Mills V, Rönnback M, Thomas S, Forsblom C, Cooper ME, Taskinen MR, Viberti G, Groop PH. Serum lipids and the progression of nephropathy in type 1 diabetes. Diabetes Care 29: 317-322, 2006.
20. Tonolo G, Melis MG, Formato M, Angius MF, Carboni A, Brizzi P, Ciccarese M, Cherchi GM, Maioli M. Additive effects of Simvastatin beyond its effects on LDL cholesterol in hypertensive type 2 diabetic patients. Eur J Clin Invest 30: 980-987, 2000.
21. Tonolo G, Velussi M, Brocco E, Abaterusso C, Carraro A, Morgia G, Satta A, Faedda R, Abhyankar A, Luthman H, Nosadini R. Simvastatin maintains steady patterns of GFR and improves AER and expression of slit diaphragm proteins in type II diabetes. Kidney Int 70: 177-186, 2006.
22. Verhulst A, D'Haese PC, De Broe ME. Inhibitors of HMG-CoA reductase reduce receptor-mediated endocytosis in human kidney proximal tubular cells. J Am Soc Nephrol 15: 2249-2257, 2004.
23. Watson AM, Li J, Schumacher C, de Gasparo M, Feng B, Thomas MC, Allen TJ, Cooper ME, Jandeleit-Dahm KA. The endothelin receptor antagonist avosentan ameliorates nephropathy and atherosclerosis in diabetic apolipoprotein E knockout mice. Diabetologia 53: 192-203, 2010.
24. Wen M, Segerer S, Dantas M, Brown PA, Hudkins KL, Goodpaster T, Kirk E, LeBoeuf RC, Alpers CE. Renal injury in apolipoprotein E-deficient mice. Lab Invest 82: 999-1006, 2002.
25. Ziyadeh FN, Hoffman BB, Han DC, Iglesias-De La Cruz MC, Hong SW, Isono M, Chen S, McGowan TA, Sharma K. Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. Proc Natl Acad Sci USA 97: 8015-8020, 2000.